Commentary

Advanced glycation endproducts in sepsis and mechanical ventilation: extra or leading man?

Marcus Baumann

Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675 Munich, Germany

Corresponding author: Marcus Baumann, marcus.baumann@lrz.tum.de

Published: 14 July 2009

Critical Care 2009, 13:164 (doi:10.1186/cc7939)

See related research by Kneyber et al., http://ccforum.com/content/13/3/R87

Abstract

Advanced glycation endproducts (AGEs) are primarily known as a complication in diabetic patients through their mediation of the inflammatory response. However, a variety of studies have demonstrated enhanced formation of AGEs in cardiovascular disorders. Despite the large number of AGEs produced during the Maillard reaction, recent focus is on the major non-crosslinking AGE Nε-carboxymethyllysine. Kneyber and colleagues focused on sepsis-induced cardiac dysfunction and investigated whether myocardial inflammation is associated with enhanced cardiac AGE deposition and whether this is further enhanced by mechanical ventilation. They showed that both conditions are associated with enhanced AGE deposition and myocardial inflammation. Therefore, AGEs may participate in the inflammatory response related to cardiac dysfunction in critically ill patients. Moreover, life-saving ventilation stimulates AGE formation in these patients. This interesting study raises the question of whether AGEs in critically ill patients are a driving force of the disease.

Advanced glycation endproducts

The advanced glycation endproduct (AGE) Nε-carboxymethyllysine (CML), as recently investigated by Kneyber and colleagues [1], can be formed either from glucose via ketoamine or glyoxal or from lipids by oxidation via glyoxal. This may explain why the pathophysiological role of AGEs is not restricted to diabetes, in which condition they have been primarily studied [2].

The enhanced formation of AGEs results in enhanced urinary excretion. In this context, renal-insufficient patients have been associated with CML values several times higher than in healthy controls. Accumulating AGEs can be observed histologically as endothelial depositions in atherosclerotic plaques and tubular cells [3-5]. Their deposition initiates increased NADPH oxidase and nuclear factor κB activity as well as a reduction in endothelial nitric oxide synthase activity [6]. These major effects cause inflammatory changes, extracellular matrix accumulation and endothelial dysfunction. Therefore, AGE accumulation is a potential target for treating inflammatory diseases.

AGEs in sepsis and during mechanical ventilation

The new and interesting idea of Kneyber and colleagues was to investigate the association of CML with myocardial inflammation during sepsis and the clinically relevant state of mechanical ventilation, which by itself is known to induce AGE accumulation in the lungs. This is of relevance as sepsis-induced cardiac dysfunction is a frequent complication associated with increased mortality. Therefore, they focused on a situation where AGE accumulation is increased by systemic inflammation and exacerbated by mechanical ventilation. The association of CML with myocardial inflammation in sepsis and mechanical ventilation is intriguing. Indeed, sepsis enhances CML deposition, which is further aggravated by mechanical ventilation. Thus, the myocardial deposition of AGEs is associated with the disease and the therapeutic approach of mechanical ventilation perpetuates AGE formation.

Opposing AGE effects in cardiovascular animal models

These results raise the question, however, whether the association reflects a relevant pathophysiological mechanism or ‘only’ reflects the critical disease state. In the former case, interfering with the production or accumulation of AGEs could provide possible treatments. One option is to administer soluble RAGE - the extracellular ligand-binding domain of RAGE, the AGE receptor - which binds AGEs and thereby limits the deleterious effects of AGEs. In animal experiments, treatment with soluble RAGE ameliorated inflammation and significantly reduced the atherosclerotic lesion area in a glycemia- and lipid-independent manner [7].

AGE = advanced glycation endproduct; CML = Nε-carboxymethyllysine.
Another pharmacological option is blockade of AGE formation by substances such as aminoguanidine or pyridoxamine. These have also been proven to prevent age-related cardiac hypertrophy in the absence of changes in collagen and elastin content [8] and diabetic complications in animal models [9]. These different approaches to treat AGE accumulation and the pathophysiological relevance of AGE formation in sepsis and mechanical ventilation need to be addressed in future studies using either soluble RAGE or blockers of AGE formation.

**AGEs in human cardiovascular disorders**

Several cross-sectional studies have documented that AGE-induced inflammation is also present in human diseases with chronic low-grade inflammation and has also been associated with diabetic microangiopathy [10], endothelial dysfunction [11], atherosclerosis [3] and chronic heart failure [12]. However, in a prospective substudy of the Iberasertan Type 2 Diabetic Nephropathy Trial (IDNT) cohort including 450 patients with nephropathy caused by type 2 diabetes, CML was not predictive for cardiovascular events [13]. Therefore, it remains uncertain whether CML is of cardiovascular relevance in humans.

**Conclusions and outlook**

Kneyber and colleagues present an interesting association between a major non-cross-linking AGE and sepsis combined with mechanical ventilation. Whether this association reflects a pathophysiologically relevant characteristic needs to be investigated in future studies. However, if interventional studies demonstrate positive effects in animal models, the availability of safe and cheap agents may offer an opportunity to target myocardial inflammation in sepsis and mechanical ventilation.

**Competing interests**

The author declares that they have no competing interests.

**References**

1. Kneyber MCJ, Gazendam RP, Niessen HWM, Kuiper JW, Dos Santos CC, Slutsky AS, Plotz FB: Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation. *Crit Care* 2009, 13:R87.
2. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloï-Michel M, Wautier JL: N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. *Diabetes Metab* 2003, 29:44-52.
3. Baidoshvili A, Niessen HW, Stocker W, Huynhbrugs RA, Hack CE, Rauwerda JA, Meijer CJ, Eijman L, van Hinsbergh VV, Schalkwijk CG: N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. *Atherosclerosis* 2004, 174:287-292.
4. Baumann M, Caron M, Schmaderer C, Schulte C, Vlekkiy O, von Weyhern CW, Lutz J, Heemann U: Renal N(epislon)-carboxymethyllysine deposition after kidney transplantation. *Transplantation* 2008, 86:330-335.
5. Baumann M, Stehouwer C, Scheijen J, Heemann U, Struijker Boudier H, Schalkwijk C: N(epislon)-carboxymethyl-lysine is increased in plasma and kidney of spontaneous hypertensive rats during the early development of hypertension and is independent of renal function or oxidative stress. *Ann N Y Acad Sci* 2008, 1126:201-204.
6. Jandeleit-Dahm K, Cooper ME: The role of AGEs in cardiovascular disease. *Curr Pharm Des* 2008, 14:979-986.
7. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF: RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. *Atherosclerosis* 2006, 185:70-77.
8. Corman B, Duriez M, Poitevin P, Heudes D, Brunel P, Tedgui A, Levy B: Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. *Proc Natl Acad Sci USA* 1998, 95:1301-1306.
9. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ, Cooper ME: Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. *Diabetologia* 2004, 47:89-97.
10. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, Stahl P: Elevated serum levels of N(epislon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. *Diabetologia* 2004, 47:1376-1379.
11. Lieuw AFML, van Hinsbergh VW, Teerlink T, Barto R, Twisk J, Stehouwer CD, Schalkwijk CG: Increased levels of N(epislon)-(carboxymethyl)lysine and N(epislon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. *Nephrol Dial Transplant* 2004, 19:631-636.
12. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ: Clinical and prognostic value of advanced glycation end-products in chronic heart failure. *Eur Heart J* 2007, 28:2879-2885.
13. Busch M, Franke S, Wolf G, Brandstadt A, Ott U, Gerth J, Hunsicker LG, Stein G: The advanced glycation end product N(epislon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. *Am J Kidney Dis* 2006, 48:571-579.